Nasdaq Gains Over 100 Points; Wells Fargo Earnings Top Views
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 15 2025
0mins
Should l Buy SLP?
Source: Benzinga
Stock Market Performance: U.S. stocks showed mixed results with the Nasdaq rising by 0.71%, while the Dow fell by 0.57%. Wells Fargo reported better-than-expected second-quarter earnings, contributing to positive sentiment in the market.
Sector Movements and Commodities: Information technology shares increased by 1.6%, whereas materials stocks declined by 0.9%. In commodities, oil and gold prices experienced slight decreases, while European and Asian markets closed mixed.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLP
Wall Street analysts forecast SLP stock price to rise
5 Analyst Rating
2 Buy
3 Hold
0 Sell
Moderate Buy
Current: 13.370
Low
19.00
Averages
19.00
High
19.00
Current: 13.370
Low
19.00
Averages
19.00
High
19.00
About SLP
Simulations Plus, Inc. specializes in model-informed and artificial intelligence (AI)-accelerated drug development. The Company helps its clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through science-based software and consulting solutions. The Company’s segments include Software and Services. The Company's Software segment supports pharmaceutical research, development, and commercialization through simulation, modeling, and AI-driven prediction. Its main products include GastroPlus, ADMET Predictor, MonolixSuite, and others for disease modeling and training, as well as Pro-ficiency for clinical operations. Its Services segment includes advanced consulting services across the entire drug development lifecycle. Its scientists and engineers specialize in drug discovery, pharmacokinetics, pharmacodynamics, drug modeling, clinical trial data analysis, regulatory strategy, and medical communications.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Market Dynamics: Stock futures are essentially flat, reflecting a cautious market waiting for confirmation, with momentum from earlier in the week fading as investors remain on the sidelines regarding future trends.
- Oil Price Movement: Oil prices are creeping higher again, hovering near the $100 per barrel level, primarily due to doubts about the durability of the ceasefire and ongoing disruptions in the Strait of Hormuz, indicating persistent inflationary pressures.
- CPI Report Impact: The Consumer Price Index (CPI) report showed the sharpest year-over-year price increases for consumers in nearly four years, largely driven by the recent energy shock, and despite a pause in fighting, oil flows remain constrained and supply chains are still disrupted.
- Stock Market Performance: In pre-market trading, S&P 500 futures rose 0.14%, Nasdaq futures rose 0.21%, and Dow futures rose 0.02%, reflecting a cautiously optimistic sentiment in the market regarding future developments.
See More
- Revenue Growth: Simulations Plus reported Q2 revenue of $24.3 million, an 8% year-over-year increase, with software revenue rising 9% to $14.6 million and services revenue also increasing by 8%, indicating sustained growth potential in the healthcare tech sector.
- Net Income Improvement: Non-GAAP net income rose 13% to over $7 million, or $0.35 per share, exceeding analyst expectations of $0.31, demonstrating enhanced profitability for the company.
- Guidance Adjustment: Despite strong performance, the company lowered its full-year adjusted net income guidance to $0.75 to $0.85 per share from a previous forecast of $1.03 to $1.10, primarily due to a higher effective tax rate, which may dampen investor sentiment.
- Market Reaction: Although the market reacted lukewarm with a mere 0.4% increase in stock price, analysts believe the company's robust performance and ongoing growth momentum in both software and services make it a worthwhile investment.
See More
- Significant Revenue Growth: Simulations Plus reported $24.3 million in revenue for Q2 2026, an 8% year-over-year increase, with software revenue rising 9% to $14.6 million and service revenue also increasing by 8%, indicating strong performance in the healthcare tech sector.
- Profit Exceeds Expectations: The non-GAAP net income rose 13% to $7 million, or $0.35 per share, surpassing analyst expectations of $0.31, reflecting an improvement in the company's profitability.
- Full-Year Guidance Cut: Despite the strong Q2 results, Simulations Plus lowered its full-year adjusted net income forecast to $0.75 to $0.85 per share, down from the previous estimate of $1.03 to $1.10, primarily due to a higher effective tax rate.
- Mild Market Reaction: Although the company exceeded expectations, its stock only rose 0.4%, indicating investor uncertainty regarding future profitability, which may affect short-term investor confidence.
See More
- Revenue Growth: Simulations Plus reported Q2 revenue of $24.3 million, an 8% year-over-year increase, with software revenue rising 9% to $14.6 million and services revenue also increasing by 8%, indicating strong demand and market recognition in the healthcare tech sector.
- Profit Improvement: Non-GAAP net income increased by 13% to over $7 million, or $0.35 per share, surpassing analyst expectations of $0.31, reflecting the company's robust profitability amidst growth.
- Guidance Cut: Despite solid performance, Simulations Plus lowered its full-year adjusted net income guidance to $0.75 to $0.85 per share from a previous forecast of $1.03 to $1.10, primarily due to a higher effective tax rate, which may dampen investor confidence.
- Market Reaction: Although the company exceeded expectations, its stock only rose by 0.4%, indicating market uncertainty regarding future profitability, prompting investors to carefully assess its long-term investment value.
See More

- Earnings Beat: Simulations Plus reported $24.3 million in revenue for Q2, exceeding expectations with growth in both software and service segments, highlighting the company's robust performance in the biosimulation sector.
- Profitability Improvement: Adjusted EBITDA reached $8.7 million, reflecting a 36% margin, aligning with internal expectations and demonstrating success in cost control and operational efficiency.
- Favorable Market Conditions: CEO Shawn O'Connor noted encouraging global market conditions, with a pickup in client spending reflected in solid software renewal rates and increased new logo activity, indicating a recovery in market demand.
- Potential for Stock Rebound: Despite a 28% decline in stock price year-to-date, the strong earnings and positive market outlook may provide momentum for a rebound, attracting investor interest.
See More
- Market Volatility: U.S. stock futures exhibited mixed movements following initial relief from the U.S.-Iran ceasefire, as doubts about its sustainability arose due to ongoing regional tensions, pushing oil prices back toward the $100 mark and limiting equity gains.
- Simulations Plus Strong Performance: Simulations Plus (SLP) shares surged 14% after reporting a Q2 non-GAAP EPS of $0.35, exceeding estimates, with revenue rising 8.3% year-over-year to $24.3 million; despite lowering FY2026 EPS guidance to $0.75–$0.85, investor optimism remained due to solid execution and a targeted EBITDA margin of 26%–30%.
- TSMC Revenue Growth: Taiwan Semiconductor Manufacturing (TSM) shares increased by 2% after reporting March 2026 revenue of NT$415.19 billion, a 45.2% year-over-year and 30.7% sequential increase, driven by robust demand for AI-related chips, with Q1 revenue of NT$1.13 trillion slightly surpassing consensus, reinforcing momentum in advanced-node demand.
- Tecnoglass Outlook Adjustment: Tecnoglass (TGLS) shares fell 6% as the company revised its FY2026 outlook to account for the impact of a newly implemented 10% U.S. tariff on aluminum window imports, now guiding for adjusted EBITDA of $225 million to $245 million, implying a ~$50 million hit compared to the prior midpoint, with management outlining mitigation steps but expecting only partial offset in 2026.
See More










